Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Neuropilin-2 gene expression correlates with malignant progression in cutaneous melanoma.

Rossi M, Tuck J, Kim OJ, Panova I, Symanowski JT, Mahalingam M, Riker AI, Alani RM, Ryu B.

Br J Dermatol. 2014 Aug;171(2):403-8. doi: 10.1111/bjd.12801. Epub 2014 Jun 11.

PMID:
24359286
2.

Gene expression profiling of primary cutaneous melanoma and clinical outcome.

Winnepenninckx V, Lazar V, Michiels S, Dessen P, Stas M, Alonso SR, Avril MF, Ortiz Romero PL, Robert T, Balacescu O, Eggermont AM, Lenoir G, Sarasin A, Tursz T, van den Oord JJ, Spatz A; Melanoma Group of the European Organization for Research and Treatment of Cancer.

J Natl Cancer Inst. 2006 Apr 5;98(7):472-82.

PMID:
16595783
3.

Differential expression of microRNAs during melanoma progression: miR-200c, miR-205 and miR-211 are downregulated in melanoma and act as tumour suppressors.

Xu Y, Brenn T, Brown ER, Doherty V, Melton DW.

Br J Cancer. 2012 Jan 31;106(3):553-61. doi: 10.1038/bjc.2011.568. Epub 2012 Jan 5.

4.

Neuropilin 1 and neuropilin 2 co-expression is significantly correlated with increased vascularity and poor prognosis in nonsmall cell lung carcinoma.

Kawakami T, Tokunaga T, Hatanaka H, Kijima H, Yamazaki H, Abe Y, Osamura Y, Inoue H, Ueyama Y, Nakamura M.

Cancer. 2002 Nov 15;95(10):2196-201.

5.

Prognostic significance of VEGF-C, semaphorin 3F, and neuropilin-2 expression in oral squamous cell carcinomas and their relationship with lymphangiogenesis.

Zhang B, Gao Z, Sun M, Li H, Fan H, Chen D, Zheng J.

J Surg Oncol. 2015 Mar 15;111(4):382-8. doi: 10.1002/jso.23842. Epub 2014 Dec 4.

PMID:
25475162
6.

Neuropilin-2 as a useful marker in the differentiation between Spitzoid malignant melanoma and Spitz nevus.

Wititsuwannakul J, Mason AR, Klump VR, Lazova R.

J Am Acad Dermatol. 2013 Jan;68(1):129-37. doi: 10.1016/j.jaad.2012.07.009. Epub 2012 Sep 3.

PMID:
22954749
7.

Differential gene expression profiling of primary cutaneous melanoma and sentinel lymph node metastases.

Koh SS, Wei JP, Li X, Huang RR, Doan NB, Scolyer RA, Cochran AJ, Binder SW.

Mod Pathol. 2012 Jun;25(6):828-37. doi: 10.1038/modpathol.2012.32. Epub 2012 Mar 9.

8.
9.

Neuropilin-2: a novel biomarker for malignant melanoma?

Rushing EC, Stine MJ, Hahn SJ, Shea S, Eller MS, Naif A, Khanna S, Westra WH, Jungbluth AA, Busam KJ, Mahalingam M, Alani RM.

Hum Pathol. 2012 Mar;43(3):381-9. doi: 10.1016/j.humpath.2011.05.008. Epub 2011 Aug 15.

10.

Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions.

Massi D, Franchi A, Sardi I, Magnelli L, Paglierani M, Borgognoni L, Maria Reali U, Santucci M.

J Pathol. 2001 Jun;194(2):194-200.

PMID:
11400148
11.

Molecular classification of melanomas and nevi using gene expression microarray signatures and formalin-fixed and paraffin-embedded tissue.

Koh SS, Opel ML, Wei JP, Yau K, Shah R, Gorre ME, Whitman E, Shitabata PK, Tao Y, Cochran AJ, Abrishami P, Binder SW.

Mod Pathol. 2009 Apr;22(4):538-46. doi: 10.1038/modpathol.2009.8. Epub 2009 Mar 6.

12.
13.

Neuropilin-2 promotes melanoma growth and progression in vivo.

Moriarty WF, Kim E, Gerber SA, Hammers H, Alani RM.

Melanoma Res. 2016 Aug;26(4):321-8. doi: 10.1097/CMR.0000000000000190.

PMID:
26881875
14.

Expression of Neuropilin-2 in salivary adenoid cystic carcinoma: its implication in tumor progression and angiogenesis.

Cai Y, Wang R, Zhao YF, Jia J, Sun ZJ, Chen XM.

Pathol Res Pract. 2010 Dec 15;206(12):793-9. doi: 10.1016/j.prp.2010.08.001. Epub 2010 Sep 20.

PMID:
20851535
15.

p53 gene mutation and expression in naevi and melanomas.

Sparrow LE, Soong R, Dawkins HJ, Iacopetta BJ, Heenan PJ.

Melanoma Res. 1995 Apr;5(2):93-100.

PMID:
7620345
16.

Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver.

Gray MJ, Van Buren G, Dallas NA, Xia L, Wang X, Yang AD, Somcio RJ, Lin YG, Lim S, Fan F, Mangala LS, Arumugam T, Logsdon CD, Lopez-Berestein G, Sood AK, Ellis LM.

J Natl Cancer Inst. 2008 Jan 16;100(2):109-20. doi: 10.1093/jnci/djm279. Epub 2008 Jan 8. Erratum in: J Natl Cancer Inst. 2008 Mar 19;100(6):446.

PMID:
18182619
17.

Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma.

Scala S, Ottaiano A, Ascierto PA, Cavalli M, Simeone E, Giuliano P, Napolitano M, Franco R, Botti G, Castello G.

Clin Cancer Res. 2005 Mar 1;11(5):1835-41.

18.

Increase in telomerase activity during progression of melanocytic cells from melanocytic naevi to malignant melanomas.

Glaessl A, Bosserhoff AK, Buettner R, Hohenleutner U, Landthaler M, Stolz W.

Arch Dermatol Res. 1999 Feb-Mar;291(2-3):81-7.

PMID:
10195394
19.

Association of galectin-3 expression with melanoma progression and prognosis.

Brown ER, Doig T, Anderson N, Brenn T, Doherty V, Xu Y, Bartlett JM, Smyth JF, Melton DW.

Eur J Cancer. 2012 Apr;48(6):865-74. doi: 10.1016/j.ejca.2011.09.003. Epub 2011 Nov 7.

PMID:
22071132
20.

Expression of matrilysin (matrix metalloproteinase-7) in primary cutaneous and metastatic melanoma.

Kawasaki K, Kawakami T, Watabe H, Itoh F, Mizoguchi M, Soma Y.

Br J Dermatol. 2007 Apr;156(4):613-9.

PMID:
17493064

Supplemental Content

Support Center